Serum bilirubin and the risk of chronic obstructive pulmonary disease exacerbations.

Serum bilirubin and the risk of chronic obstructive pulmonary disease exacerbations.
复制标题

DOI:
10.1186/s12931-017-0664-0
复制
发表时间:
2017-10-24
影响因子:
5.8
通讯作者:
COPD Clinical Research Network
COPD Clinical Research Network
中科院分区:
医学2区
文献类型:
--
作者:
Brown KE;Sin DD;Voelker H;Connett JE;Niewoehner DE;Kunisaki KM;COPD Clinical Research Network

文献摘要

参考文献

被引文献

相似文献

Bilirubin is a potent anti-oxidant and higher serum concentrations of bilirubin have been associated with better lung function, slower lung function decline, and lower incidence of chronic obstructive pulmonary disease (COPD). We sought to determine whether elevated bilirubin blood concentrations are associated with lower risk for acute exacerbations of COPD (AECOPD). We performed a secondary analyses of data in the Simvastatin for Prevention of Exacerbations in Moderate-to-Severe COPD (STATCOPE) and the Azithromycin for Prevention of Exacerbations of COPD (MACRO) studies. We used time-dependent multivariable Cox proportional hazards analyses, using bilirubin concentrations prior to first AECOPD as the exposure variable and time to first AECOPD as the outcome variable. STATCOPE was used for model development, with validation in MACRO. In STATCOPE (n = 853), higher bilirubin was associated with a lower but statistically insignificant hazard for AECOPD, (adjusted hazard ratio [aHR] 0.89 per log10 increase [95%CI: 0.74 to 1.09; p = 0.26]). In the validation MACRO study (n = 1018), higher bilirubin was associated with a significantly lower hazard for AECOPD (aHR 0.80 per log10 increase [95%CI: 0.67 to 0.94; p = 0.008]). Bilirubin may be a biomarker of AECOPD risk and may be a novel therapeutic target to reduce AECOPD risk. ClinicalTrials.gov NCT01061671 (registered 02 February 2010) and ClinicalTrials.gov NCT00325897 (registered 12 May 2006).
DOI: 10.1136/bmjopen-2014-006720
发表时间: 2014-12-19
期刊: BMJ open
影响因子: 2.9
作者:
Schmidt SA;Johansen MB;Olsen M;Xu X;Parker JM;Molfino NA;Lash TL;Sørensen HT;Christiansen CF
通讯作者: Christiansen CF
DOI: 10.1016/j.clinbiochem.2009.05.007
发表时间: 2009-08-01
影响因子: 2.8
作者:
Lo, Stanley F.;Kytzia, Hans-Joachim;Doumas, Basil T.
通讯作者: Doumas, Basil T.
DOI: 10.1111/j.1365-2796.2012.02576.x
发表时间: 2013-01-01
影响因子: 11.1
作者:
Stender, S.;Frikke-Schmidt, R.;Tybjaerg-Hansen, A.
通讯作者: Tybjaerg-Hansen, A.
DOI: 10.1016/j.bbrc.2015.07.133
发表时间: 2015-09-18
影响因子: 3.1
作者:
Wei, Jingjing;Zhao, Hui;Li, Jianqiang
通讯作者: Li, Jianqiang
DOI: 10.1183/09031936.00055813
发表时间: 2014-05-01
影响因子: 24.3
作者:
Curjuric, Ivan;Imboden, Medea;Probst-Hensch, Nicole M.
通讯作者: Probst-Hensch, Nicole M.